File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.jcjo.2019.10.011
- Scopus: eid_2-s2.0-85076860390
- PMID: 31879067
- WOS: WOS:000540442800017
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Polypoidal choroidal vasculopathy in Canada
Title | Polypoidal choroidal vasculopathy in Canada |
---|---|
Authors | |
Issue Date | 2020 |
Publisher | Elsevier for the Canadian Ophthalmological Society. The Journal's web site is located at http://www.canadianjournalofophthalmology.ca |
Citation | Canadian Journal of Ophthalmology, 2020, v. 55, p. 199-211 How to Cite? |
Abstract | Polypoidal choroidal vasculopathy (PCV) is an exudative age-related macular degeneration (AMD) subtype found more frequently among Asians than Caucasians. If untreated, it may lead to severe vision loss. PCV appears to be frequently underdiagnosed in Canada, although misdiagnosis of PCV as AMD carries the risk of inadequate treatment and unsatisfactory clinical outcomes. Diagnosis can be made on the basis of multimodal imaging, including optical coherence tomography (OCT) and OCT angiography combined with colour fundus photography, or by other imaging techniques; the gold-standard indocyanine green angiography (ICGA) is not widely used in Canada. Treatment involves anti-vascular endothelial growth factor (anti-VEGF) agents (bevacizumab, ranibizumab, or aflibercept), alone or in combination with photodynamic therapy (PDT). Recent clinical trials have shown that ranibizumab in combination with PDT is superior to ranibizumab monotherapy (EVEREST II), and aflibercept monotherapy is as effective in patients meeting PDT rescue criteria as aflibercept combined with rescue PDT (PLANET). It appears that most Canadian PCV patients are treated with anti-VEGF monotherapy, with or without PDT. |
Description | Hybrid open access |
Persistent Identifier | http://hdl.handle.net/10722/295762 |
ISSN | 2021 Impact Factor: 2.592 2020 SCImago Journal Rankings: 0.612 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lam, WC | - |
dc.contributor.author | Choudhry, N | - |
dc.contributor.author | Wong, D | - |
dc.date.accessioned | 2021-02-08T08:13:39Z | - |
dc.date.available | 2021-02-08T08:13:39Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Canadian Journal of Ophthalmology, 2020, v. 55, p. 199-211 | - |
dc.identifier.issn | 0008-4182 | - |
dc.identifier.uri | http://hdl.handle.net/10722/295762 | - |
dc.description | Hybrid open access | - |
dc.description.abstract | Polypoidal choroidal vasculopathy (PCV) is an exudative age-related macular degeneration (AMD) subtype found more frequently among Asians than Caucasians. If untreated, it may lead to severe vision loss. PCV appears to be frequently underdiagnosed in Canada, although misdiagnosis of PCV as AMD carries the risk of inadequate treatment and unsatisfactory clinical outcomes. Diagnosis can be made on the basis of multimodal imaging, including optical coherence tomography (OCT) and OCT angiography combined with colour fundus photography, or by other imaging techniques; the gold-standard indocyanine green angiography (ICGA) is not widely used in Canada. Treatment involves anti-vascular endothelial growth factor (anti-VEGF) agents (bevacizumab, ranibizumab, or aflibercept), alone or in combination with photodynamic therapy (PDT). Recent clinical trials have shown that ranibizumab in combination with PDT is superior to ranibizumab monotherapy (EVEREST II), and aflibercept monotherapy is as effective in patients meeting PDT rescue criteria as aflibercept combined with rescue PDT (PLANET). It appears that most Canadian PCV patients are treated with anti-VEGF monotherapy, with or without PDT. | - |
dc.language | eng | - |
dc.publisher | Elsevier for the Canadian Ophthalmological Society. The Journal's web site is located at http://www.canadianjournalofophthalmology.ca | - |
dc.relation.ispartof | Canadian Journal of Ophthalmology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | Polypoidal choroidal vasculopathy in Canada | - |
dc.type | Article | - |
dc.identifier.email | Lam, WC: waichlam@hku.hk | - |
dc.identifier.authority | Lam, WC=rp02162 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1016/j.jcjo.2019.10.011 | - |
dc.identifier.pmid | 31879067 | - |
dc.identifier.scopus | eid_2-s2.0-85076860390 | - |
dc.identifier.hkuros | 321095 | - |
dc.identifier.volume | 55 | - |
dc.identifier.spage | 199 | - |
dc.identifier.epage | 211 | - |
dc.identifier.isi | WOS:000540442800017 | - |
dc.publisher.place | United States | - |